Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients

Taichi Ochi, Natalya M. Vyalova, Innokentiy S. Losenkov, Lyudmila A. Levchuk, Diana Z. Osmanova, Ekaterina V. Mikhalitskaya, Anton J.M. Loonen, Fokko J. Bosker, German G. Simutkin, Nikolay A. Bokhan, Bob Wilffert, Svetlana A. Ivanova

Research output: Contribution to journalArticle

Abstract

Background: Brain-derived neurotrophic factor (BDNF) is associated with response to antidepressant drugs in mood and anxiety disorders. Prolactin (PRL) is a pituitary hormone with behavioural effects, acting as a neurotrophic factor within the brain and may be involved in antidepressant response. Objectives: To investigate the relationship between BDNF and PRL genotypes with antidepressant drug response. Methods: Prospective inception cohort of 186 Russian treatment-free participants (28 men and 158 women) between 18 and 70 years clinically diagnosed with depressive disorder who initiated antidepressant medication. DNA polymorphisms were genotyped for PRL rs1341239, BDNF rs6265 and rs7124442. Primary outcome was measured by differences in Hamilton Depression Rating Scale (∆HAM-D) scores between baseline/week two, week two/week four, and baseline/week four. Linear regression and independent t-test determined the significance between polymorphisms and ∆HAM-D. Results: Comparisons between genotypes did not reveal any significant differences in scores during the first two weeks of treatment. In the latter two weeks, BDNF rs7124442 homozygous C patients responded significantly worse in comparison to homozygous T patients during this period. Further analysis within women and in post-menopausal women found a similar comparison between alleles. Limitations: Study lasted four weeks, which may be considered short to associate genuine antidepressant effects. Conclusions: Patients taking tricylic antidepressants were noted to have a significant improvement in ∆HAM-D compared to patients taking SSRIs. Homozygous C BDNF rs712442 patients were found to respond significantly worse in the last two weeks of treatment.

Original languageEnglish
Pages (from-to)432-439
Number of pages8
JournalJournal of Affective Disorders
Volume259
DOIs
Publication statusPublished - 1 Dec 2019

Fingerprint

Brain-Derived Neurotrophic Factor
Prolactin
Antidepressive Agents
Cohort Studies
Genotype
Depression
Therapeutics
Pituitary Hormones
Nerve Growth Factors
Depressive Disorder
Anxiety Disorders
Mood Disorders
Linear Models
Alleles
DNA
Brain

Keywords

  • Antidepressant response
  • Brain derived neurotrophic factor
  • Major depressive disorder
  • Prolactin
  • rs6265
  • rs7124442

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients : A prospective inception cohort study in treatment-free patients. / Ochi, Taichi; Vyalova, Natalya M.; Losenkov, Innokentiy S.; Levchuk, Lyudmila A.; Osmanova, Diana Z.; Mikhalitskaya, Ekaterina V.; Loonen, Anton J.M.; Bosker, Fokko J.; Simutkin, German G.; Bokhan, Nikolay A.; Wilffert, Bob; Ivanova, Svetlana A.

In: Journal of Affective Disorders, Vol. 259, 01.12.2019, p. 432-439.

Research output: Contribution to journalArticle

Ochi, T, Vyalova, NM, Losenkov, IS, Levchuk, LA, Osmanova, DZ, Mikhalitskaya, EV, Loonen, AJM, Bosker, FJ, Simutkin, GG, Bokhan, NA, Wilffert, B & Ivanova, SA 2019, 'Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients', Journal of Affective Disorders, vol. 259, pp. 432-439. https://doi.org/10.1016/j.jad.2019.08.058
Ochi, Taichi ; Vyalova, Natalya M. ; Losenkov, Innokentiy S. ; Levchuk, Lyudmila A. ; Osmanova, Diana Z. ; Mikhalitskaya, Ekaterina V. ; Loonen, Anton J.M. ; Bosker, Fokko J. ; Simutkin, German G. ; Bokhan, Nikolay A. ; Wilffert, Bob ; Ivanova, Svetlana A. / Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients : A prospective inception cohort study in treatment-free patients. In: Journal of Affective Disorders. 2019 ; Vol. 259. pp. 432-439.
@article{bc4e3db184514a17820adc9fd5b12b6c,
title = "Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients",
abstract = "Background: Brain-derived neurotrophic factor (BDNF) is associated with response to antidepressant drugs in mood and anxiety disorders. Prolactin (PRL) is a pituitary hormone with behavioural effects, acting as a neurotrophic factor within the brain and may be involved in antidepressant response. Objectives: To investigate the relationship between BDNF and PRL genotypes with antidepressant drug response. Methods: Prospective inception cohort of 186 Russian treatment-free participants (28 men and 158 women) between 18 and 70 years clinically diagnosed with depressive disorder who initiated antidepressant medication. DNA polymorphisms were genotyped for PRL rs1341239, BDNF rs6265 and rs7124442. Primary outcome was measured by differences in Hamilton Depression Rating Scale (∆HAM-D) scores between baseline/week two, week two/week four, and baseline/week four. Linear regression and independent t-test determined the significance between polymorphisms and ∆HAM-D. Results: Comparisons between genotypes did not reveal any significant differences in scores during the first two weeks of treatment. In the latter two weeks, BDNF rs7124442 homozygous C patients responded significantly worse in comparison to homozygous T patients during this period. Further analysis within women and in post-menopausal women found a similar comparison between alleles. Limitations: Study lasted four weeks, which may be considered short to associate genuine antidepressant effects. Conclusions: Patients taking tricylic antidepressants were noted to have a significant improvement in ∆HAM-D compared to patients taking SSRIs. Homozygous C BDNF rs712442 patients were found to respond significantly worse in the last two weeks of treatment.",
keywords = "Antidepressant response, Brain derived neurotrophic factor, Major depressive disorder, Prolactin, rs6265, rs7124442",
author = "Taichi Ochi and Vyalova, {Natalya M.} and Losenkov, {Innokentiy S.} and Levchuk, {Lyudmila A.} and Osmanova, {Diana Z.} and Mikhalitskaya, {Ekaterina V.} and Loonen, {Anton J.M.} and Bosker, {Fokko J.} and Simutkin, {German G.} and Bokhan, {Nikolay A.} and Bob Wilffert and Ivanova, {Svetlana A.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1016/j.jad.2019.08.058",
language = "English",
volume = "259",
pages = "432--439",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",

}

TY - JOUR

T1 - Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients

T2 - A prospective inception cohort study in treatment-free patients

AU - Ochi, Taichi

AU - Vyalova, Natalya M.

AU - Losenkov, Innokentiy S.

AU - Levchuk, Lyudmila A.

AU - Osmanova, Diana Z.

AU - Mikhalitskaya, Ekaterina V.

AU - Loonen, Anton J.M.

AU - Bosker, Fokko J.

AU - Simutkin, German G.

AU - Bokhan, Nikolay A.

AU - Wilffert, Bob

AU - Ivanova, Svetlana A.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Background: Brain-derived neurotrophic factor (BDNF) is associated with response to antidepressant drugs in mood and anxiety disorders. Prolactin (PRL) is a pituitary hormone with behavioural effects, acting as a neurotrophic factor within the brain and may be involved in antidepressant response. Objectives: To investigate the relationship between BDNF and PRL genotypes with antidepressant drug response. Methods: Prospective inception cohort of 186 Russian treatment-free participants (28 men and 158 women) between 18 and 70 years clinically diagnosed with depressive disorder who initiated antidepressant medication. DNA polymorphisms were genotyped for PRL rs1341239, BDNF rs6265 and rs7124442. Primary outcome was measured by differences in Hamilton Depression Rating Scale (∆HAM-D) scores between baseline/week two, week two/week four, and baseline/week four. Linear regression and independent t-test determined the significance between polymorphisms and ∆HAM-D. Results: Comparisons between genotypes did not reveal any significant differences in scores during the first two weeks of treatment. In the latter two weeks, BDNF rs7124442 homozygous C patients responded significantly worse in comparison to homozygous T patients during this period. Further analysis within women and in post-menopausal women found a similar comparison between alleles. Limitations: Study lasted four weeks, which may be considered short to associate genuine antidepressant effects. Conclusions: Patients taking tricylic antidepressants were noted to have a significant improvement in ∆HAM-D compared to patients taking SSRIs. Homozygous C BDNF rs712442 patients were found to respond significantly worse in the last two weeks of treatment.

AB - Background: Brain-derived neurotrophic factor (BDNF) is associated with response to antidepressant drugs in mood and anxiety disorders. Prolactin (PRL) is a pituitary hormone with behavioural effects, acting as a neurotrophic factor within the brain and may be involved in antidepressant response. Objectives: To investigate the relationship between BDNF and PRL genotypes with antidepressant drug response. Methods: Prospective inception cohort of 186 Russian treatment-free participants (28 men and 158 women) between 18 and 70 years clinically diagnosed with depressive disorder who initiated antidepressant medication. DNA polymorphisms were genotyped for PRL rs1341239, BDNF rs6265 and rs7124442. Primary outcome was measured by differences in Hamilton Depression Rating Scale (∆HAM-D) scores between baseline/week two, week two/week four, and baseline/week four. Linear regression and independent t-test determined the significance between polymorphisms and ∆HAM-D. Results: Comparisons between genotypes did not reveal any significant differences in scores during the first two weeks of treatment. In the latter two weeks, BDNF rs7124442 homozygous C patients responded significantly worse in comparison to homozygous T patients during this period. Further analysis within women and in post-menopausal women found a similar comparison between alleles. Limitations: Study lasted four weeks, which may be considered short to associate genuine antidepressant effects. Conclusions: Patients taking tricylic antidepressants were noted to have a significant improvement in ∆HAM-D compared to patients taking SSRIs. Homozygous C BDNF rs712442 patients were found to respond significantly worse in the last two weeks of treatment.

KW - Antidepressant response

KW - Brain derived neurotrophic factor

KW - Major depressive disorder

KW - Prolactin

KW - rs6265

KW - rs7124442

UR - http://www.scopus.com/inward/record.url?scp=85071718271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071718271&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2019.08.058

DO - 10.1016/j.jad.2019.08.058

M3 - Article

AN - SCOPUS:85071718271

VL - 259

SP - 432

EP - 439

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

ER -